D. Floch

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.

D. Isenberg, M. Rotte, W. Ng, 2020, The Lancet. Rheumatology.

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

G. Sunkara, A. Chakraborty, D. Howard, 2013, Journal of clinical pharmacology.

Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects

H. Wallny, C. Reynolds, Sivanaga S Anumolu, 2018, Clinical pharmacology in drug development.

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

H. Gram, A. Chakraborty, S. Tannenbaum, 2012, Clinical Pharmacokinetics.

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

J. Arm, S. Maahs, P. Lowe, 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis

Xuemin Jiang, G. Sunkara, K. Abrams, 2016, Journal of clinical pharmacology.

Novel Anti-CD40 Monoclonal Antibody CFZ533 in Patients with Primary Sjogren Syndrome: A Phase Iia Double-Blind, Placebo–Controlled Randomized Trial

D. Isenberg, M. Rotte, W. Ng, 2018, Oral surgery, oral medicine, oral pathology and oral radiology.